Dermatology Department. Complejo Hospitalario Universitario Insular Materno-Infantil. Gran Canaria Dermatology Department. Hospital Virgen de los Reyes. El Hierro Research Unit. Hospital Universitario Nuestra Señora de Candelaria. Universidad de La Laguna. Tenerife Dermatology Department. Hospital del Mar. Universitat Autònoma de Barcelona. Barcelona. Dermatology Department. Hospital Universitario 12 de Octubre. Madrid. Dermatology Department. Hospital Universitari de Bellvitge. IDIBELL. Barcelona. Dermatology Department. Hospital Clínico. University of Barcelona. Barcelona Dermatology Department. Hospital Universitario Ramón y Cajal. Madrid. Dermatology Department. Hospital Universitario Fundación Alcorcón. Madrid. Dermatology Department. Hospital de Cruces. Baracaldo. Dermatology Department. Hospital de Basurto. Bilbao. Research Unit - Dermatology Department. Hospital Universitario Nuestra Señora de Candelaria. Universidad de La Laguna. Tenerife.
Intravenous, rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients.
To evaluate the effectiveness, tolerance and adverse effects of ILR in patients with follicle centre (FCL) and marginal zone (MZL) PCBL.
This was an epidemiologic observational multicentre study of patients with PCBL treated with ILR..
Seventeen patients with MZL and 18 with FCL PCBL were included. The median number of lesions treated was 2 per patient. The treatment regimen used in 74% of the patients was courses of 3 injections in a single week at 1-month intervals. The dose per lesion and day of treatment was 10 mg in 71% of the patients. The median cumulative dose of rituximab per lesion was 60 mg (range, 13-270) and per patient was 150 mg (range, 20-360 mg). Complete response (CR) and partial response were achieved in 71% and 23% of patients, respectively.
The median time to CR in patients who received 10 mg of ILR per lesion was 8 weeks. Similar response rates were observed in MZL and FCL. Median disease-free survival was 114.1 weeks. No parameters that significantly predicted CR were identified. Adverse reactions were recorded in 19 patients. The most frequent was localised pain at the injection site. Median follow-up was 21 months.
ILR is a well tolerated and effective treatment for FCL and MZL PCBL. It should be considered a useful alternative in patients with recurrent lesions and in which the sequelae of radiotherapy or surgery would be significant.
Am old enough to understand the difference between the Bay of Pigs - and roasting a pig at a epicurian feast. Been thru the hippy, yippie and yuppie years - always remaining who I am.
Very much believe in "Sing your own song - weave your own tapestry"
Am young enough to still know the thrill of new discoveries, the beauty of the evening, to celebrate the joy of another tommorow.
Survived these many decades with a severe medical problems. Sorting out the maze of now having two lymphomas and all their nasty little companions, but I continue.
Besides, being a simple iconoclastic eclectic, have been called many things. An incurable romanticist - with a strong touch of reality. Thinker, intellectual (God, how I hate that term) - been told I am a lion with the heart of the poet.
Know how to wage war and conquer my foes - but would rather be known as one who brings hope and life. To bring hope into anothers life is the ultimate of joys.
Life should be about bringing hope, peace, vision... a sense of purpose beyond yourself.